MAPT H1h — The Sub-haplotype Connecting Tau to Parkinson's Motor Phenotype
The MAPT gene encodes tau, a microtubule-stabilising protein central to several
neurodegenerative diseases. The gene sits within a large chromosomal inversion on 17q21
that divides all humans into two broad haplotype clades: H1 (no inversion) and H2 (inverted).
H1 carriers face elevated tau-related disease risk — but H1 is not a single entity. It
encompasses a family of sub-haplotypes, each defined by a unique combination of alleles
at six tagging positions. rs3785883 defines the H1h sub-haplotype, a configuration
that carries a distinctive risk profile separate from the well-characterised H1c
sub-haplotype tracked by rs242557 and rs2471738.
The Mechanism
The rs3785883 A allele co-occurs with rs242557 G and rs2471738 C to form the H1h
sub-haplotype (full composition: rs1467967=A, rs242557=G, rs3785883=A, rs2471738=C).
This is structurally distinct from H1c (rs242557=A, rs2471738=T, rs3785883=G): the two
sub-haplotypes carry the A allele at rs3785883 and rs242557 in opposite orientations.
The linkage disequilibrium between rs3785883 and rs242557 is extremely low | r² ≈ 0.01
measured in both healthy controls and PSP patients,
confirming these SNPs are statistically and biologically independent.
The molecular consequence of the H1h configuration is not fully characterised, but the
sub-haplotype pattern implicates altered tau isoform ratios or expression levels in neurons
within specific motor circuits. The non-tremor dominant (NTD) phenotype of Parkinson's
disease — characterised by postural instability and gait difficulty rather than resting tremor
— is the clinical domain where H1h risk concentrates, suggesting a preferential effect on
basal ganglia circuitry.
The Evidence
A 2016 study examining MAPT subhaplotype architecture across PD subtypes | Ezquerra et al.
Genetic Architecture of MAPT Gene Region in Parkinson Disease Subtypes. Front Cell Neurosci,
2016 found that the H1h sub-haplotype was
overrepresented in NTD-PD patients compared with controls with an OR of 2.9 (95% CI
1.3–6.3) that survived Bonferroni correction (p = 0.007). The overall PD association
(uncorrected OR 2.6, p = 0.013) did not reach significance after correction. At the
individual-SNP level, rs3785883 showed a nominally significant association with NTD-PD
(OR 1.5, p = 0.044) that did not survive multiple-testing correction — the haplotype-level
signal is stronger than the single-SNP signal, consistent with the variant acting as part
of a combinatorial genetic background rather than as an independent causal allele.
Earlier subhaplotype work (Goris et al., 2007)
established the key contrast: rs242557 (H1c) does not alter PD risk, while rs3785883
participates in a sub-haplotype block that does — precisely the opposite of the PSP/CBD
pattern, where H1c dominates. This disease-specific partitioning of H1 sub-haplotype
risk is a central insight of MAPT genetic architecture.
A Croatian cohort study of Alzheimer's disease biomarkers found both AA and GG genotypes
at rs3785883 associated with pathological CSF and plasma biomarkers, though the authors
noted the interpretation is ambiguous and flagged it for further investigation. A meta-analysis
of MAPT variants in neurodegenerative diseases found only a nominally protective A-allele
signal in Caucasians (OR 0.87) that disappeared after sensitivity analysis, providing no
reliable AD risk signal for this SNP.
The overall evidence level is moderate: the H1h-NTD-PD association is supported by
a single well-designed study with correction for multiple testing, but has not yet been
replicated in independent cohorts. The AD biomarker data are preliminary and contradictory.
Practical Actions
Carriers of the A allele — particularly those homozygous AA — exist within the H1h
sub-haplotype background and face modestly elevated risk for the akinetic-rigid/postural-
instability variant of Parkinson's disease. The actionable implications are similar to
other MAPT risk variants: prioritising cardiovascular and metabolic health (which modifies
the timing and severity of tau-related neurodegeneration), regular monitoring for early
motor symptoms, and physical activity targeting balance and postural stability. Aerobic
exercise has been shown to promote tau clearance via glymphatic pathways and reduce
neuroinflammation, making it particularly relevant here.
Interactions
rs3785883 (H1h) and rs242557 (H1c) are nearly independent (r² ≈ 0.01) and tag distinct
disease risks: H1h → NTD-PD, H1c → PSP/CBD. An individual who carries the A allele
at rs3785883 is unlikely to also carry the A allele at rs242557 on the same chromosomal
background. Compound analysis of all six MAPT tagging positions (rs1467967, rs242557,
rs3785883, rs2471738, del-In9, rs7521) provides the most complete sub-haplotype picture.
rs17651213 (exon 3 splice regulator) adds a mechanistic layer: its G allele elevates
4-repeat tau isoforms across most H1 sub-haplotypes including H1h, potentially amplifying
the H1h motor risk signal.
All Genotypes
G/G — not on the H1h sub-haplotype background
You carry two copies of the G allele at rs3785883, which means you are not on the H1h MAPT sub-haplotype. The H1h configuration (which carries the A allele here alongside a specific combination of alleles at nearby positions) has been associated with a higher rate of non-tremor dominant Parkinson's disease. Your GG genotype places you in the majority — approximately 67% of people across most ancestry groups share this result.
A/G — one copy of the H1h-defining allele
You carry one copy of the A allele at rs3785883, meaning one of your two chromosomes may carry the H1h sub-haplotype configuration. Heterozygotes make up approximately 30% of the population. The H1h sub-haplotype has been associated with non-tremor dominant Parkinson's disease (OR 2.9 at the haplotype level), though the single-SNP signal at rs3785883 is weaker and did not survive multiple-testing correction on its own. The A allele at this position is also associated with slightly elevated CSF tau levels in some studies.
A/A — homozygous for the H1h-defining allele
You carry two copies of the A allele at rs3785883, the rarest genotype at this position (approximately 3% of most populations). Both chromosomes carry the A allele associated with the H1h MAPT sub-haplotype, which has been linked to a substantially elevated risk for non-tremor dominant Parkinson's disease in one study (OR 2.9 at the haplotype level after correction for multiple testing). Two independent studies have also found that AA homozygosity at this position correlates with pathological CSF and plasma Alzheimer's disease biomarkers, though the direction and mechanism of this association remain under investigation.